Clinical use of antimicrobial pharmacodynamic profiles to optimise treatment outcomes in community-acquired bacterial respiratory tract infections: Application to telithromycin

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 2, 2004, Pages 229-235

  Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Antimicrobial (antibacterial) resistance; Community acquired respiratory infection; Ketolides; Optimal therapy; Telithromycin

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BACTERICIDE; BETA LACTAM ANTIBIOTIC; CEFPROZIL; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; KETOLIDE; LEVOFLOXACIN; LINCOSAMIDE; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOGRAMIN; TELITHROMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTERIAL INFECTION; BACTERIAL STRAIN; CLINICAL PRACTICE; COMMUNICABLE DISEASE; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG MONITORING; DRUG POTENCY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PREDICTION; PRIMARY MEDICAL CARE; QUANTITATIVE ANALYSIS; RESPIRATORY TRACT INFECTION; REVIEW; TREATMENT OUTCOME;

ANTI-INFECTIVE AGENTS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; KETOLIDES; MACROLIDES; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 1242296819     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.2.229     Document Type: Review

References (55)

1. GONZALES R, STEINER JF, SANDE MA: Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA (1997) 278:901-904.
2. MCCAIG LF, BESSER RE, HUGHES JM: Antimicrobial drug prescription in ambulatory care settings, United States, 1992 - 2000. Emerg. Infect. Dis. (2003) 9:432-437.
3. STEINMAN MA, GONZALES R, LINDER JA, LANDEFELD CS: Changing use of antibiotics in community-based outpatient practice, 1991-1999. Ann. Intern. Med. (2003) 138:525-533.
4. NORMARK BH, NORMARK S: Evolution and spread of antibiotic resistance. J. Intern. Med. (2002) 252:91-106.
5. BAQUERO F: Evolving resistance patterns of Streprococcus pneumoniae: a link with long-acting macrolide consumption? J Chemother. (1999) 11(Suppl. 0):35-43.
6. DAGAN R, KLUGMAN KP. CRAIG WA, BAQUERO F: Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J. Antimicrob. Chemother. (2001) 47:129-140.
7. BLONDEAU JM, TILLOTSON GS: Antimicrobial susceptibility patterns of respiratory pathogens - a global perspective. Semin. Respir. Infect. (2000) 15:195-207.
8. HOBAN DJ, DOERN GV, FLUIT AC, ROUSSEL-DELVALLEZ M, JONES RN: Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997 - 1999. Clin. Infect. Dis. (2001) 32(Suppl. 2):S81-S93.
9. DUNBAR LM: Current issues in the management of bacterial respiratory tract disease: the challenge of antibacterial resistance. Am. J. Med. Sci. (2003) 326:360-368.
10. GARAU J: Changing patterns of etiology and resistance in community-acquired respiratory tract infections. Infect. Dis. Clin. Pract. (1998) 7(Suppl. 2):S92-S95.
11. HEFFELFINGER JD, DOWELL SF, JORGENSEN JH et al., and the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group: management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch. Intern. Med. (2000) 160:1399-1408.
12. DOERN GV, HEILMANN KP, HUYNH HK, RHOMBERG, PR, COFFMAN SL, BRUEGGEMANN AB: Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994 - 1995. Antimicrob. Agents Chemother. (2001) 45:1721-1729.
13. GAY K, BAUGHMAN W, MILLER Y et al.: The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population-based assessment. J. Infect. Dis. (2000) 182:1417-1424.
14. BAQUERO F, BARRETT JF, COURVALIN P, MORRISSEY I, PIDDOCK L, NOVICK WJ: Epidemiology and mechanisms of resistance among respiratory tract pathogens. Clin. Microbiol. Infect. (1998) 4(Suppl. 2):S19-S26.
15. JACOBS MR: Emergence of antibiotic resistance in upper and lower respiratory tract infections. Am. J. Manag. Care. (1999) 5(Suppl.):S651-S661.
16. LOW DE, SCHELD WM: Strategies for stemming the tide of antimicrobial resistance. JAMA (1998) 279:394-395 (Editorial).
17. NICOLAU DP: Using pharmacodynamic and pharmacokinetic surrogate markers in clinical practice: optimizing antimicrobial therapy in respiratory-tract infections. Am. J. Health Syst. Pharm. (1999) 56(Suppl. 3):S16-S20.
18. NICOLAU DP, ONYEJI CO, ZHONG M, TESSIER PR, BANEVICIUS MA, NIGHTINGALE CH: Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: implications for breakpoint determinations. Antimicrob. Agents Chemother. (2000) 44:1291-1295.
19. TESSIER PR, KIM MK, ZHOU W et al.: Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob. Agents Chemother. (2002) 46:1425-1434.
20. CRAIG WA, ANDES D: Pharmacokinetics; and pharmacodynamics of antibiotics in otitis media. Pediatr. Infect. Dis. J. (1996) 15:255-259.
21. AMBROSE PG, GRASELA DM, GRASELA TH, PASSARELL J, MAYER HB, PIERCE PF: Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. (2001) 45:2793-2797.
22. NICOLAU DP, FREEMAN CD, BELLIVEAU PP, NIGHTINGALE CH, ROSS JW, QUINTILIANI R: Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob. Agents Chemother. (1995) 39:650-655.
23. DRUSANO G: Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin. Clin. Microbiol. Infect. (2001) 7(Suppl. 3):24-29.
24. NICOLAU DP: Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles. Infection (2001) 29(Suppl. 2):11-15.
25. JACOBS MK: Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol. Infect. (2001) 7:589-596.
26. MODAI J: Empiric therapy of severe infections in adults. Am. J. Med. (1990) 88:12S-17S.
27. NIEDERMAN MS, MANDELL LA, ANZUETO A et al., for the American Thoracic Society: guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. (2001) 163:1730-1754.
28. NICOLAU D: Clinical and economic implications of antimicrobial resistance for the management of community-acquired respiratory tract infections. J. Antimicrob. Chemother. (2002) 50(Suppl. S1):61-70.
29. NIEDERMAN MS: Appropriate use of antimicrobial agents: challenges and strategies for improvement. Crit. Care Med. (2003) 31:608-616.
30. FELMINGHAM D: Microbiological profile of telithromycin, the first ketolide antimicrobial. Clin. Microbiol. Infect. (2001) 7(Suppl. 3):2-10.
31. CLARK JP, LANGSTON E: Ketolides: a new class of antibacterial agents for treatment of community-acquired respiratory tract infections in a primary care setting. Mayo Clin. Proc. (2003) 78:1113-1124.
32. ROSATO A, VICARINI H, BONNEFOY A, CHANTOT JF, LECLERCQ R: A new ketolide, HMR 3004, active against streptococci inducibly resistant to erythromycin. Antimicrob. Agents Chemother (1998) 42:1392-1396.
33. AGOURIDAS C, DENIS A, AUGER J-M et al.: Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. J. Med. Chem. (1998) 41:4080-4100.
34. ZHANEL GG, WALTERS M, NOREDDIN A et al.: The ketolides: a critical review. Drugs (2002) 62:1771-1804.
35. DENIS A, AGOURIDAS C, AUGER J-M et al.: Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. Bioorg. Med. Chem. Lett. (1999) 9:3075-3080.
36. HUNTER PA: Ketolides-a novel form of macrolide: the way forward? Drug Discov. Today (1998) 3:257-260.
37. PANKUCH GA, VISALLI MA, JACOBS MR, APPELBAUM PC: Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob. Agents Chemother. (1998) 42:624-630.
38. DAVIES TA, DEWASSE BE, JACOBS MR, APPELBAUM PC: In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. (2000) 44:414-417.
39. ZHONG P, CAO Z, HAMMOND R et al: Induction of ribosome methylation in MLS-resistant Streptococcus pneumoniae by macrolides and ketolides. Microb. Drug Resist. (1999) 5:183-188.
40. DOUTHWAITE S, HANSEN LH, MAUVAIS P: Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA. Mol. Microbiol. (2000) 36:183-193.
41. CHAMPNEY WS, TOBER CL: Inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells by 11 different ketolide antibiotics. Curr. Microbiol. (1998) 37:418-425.
42. B resistance phenotype. J. Antimicrob. Chemother. (1997) 40:85-90.
43. DOUTHWAITE S: Structure - activity relationships of ketolides versus macrolides. Clin. Microbiol Infect. (2001) 7(Suppl. 3):11-17.
44. BRYSKIER A: Ketolides - telithromycin, an example of a new class of antibacterial agents. Clin. Microbiol. Infect. (2000) 6:661-669.
45. POEHLSGAARD J, DOUTHWAITE S: The macrolide binding site on the bacterial ribosome. Curr. Drug Targets Infect. Disord. (2002) 2:67-78.
46. BEMER-MELCHIOR P, JUVIN ME, TASSIN S, BRYSKIER A, SCHITO GC, DRUGEON HB: In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: influences of resistance mechanisms and methodological factors. Antimicrob. Agents Chemother. (2000) 44:2999-3002.
47. HANSEN LH, MALTVAIS P, DOUTHWAITE S: The macrolideketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Mol. Microbiol. (1999) 31:623-631.
48. MAUVAIS P, BONNEFOY A: Lack of in vitro MLSB resistance induction by the ketolide telithromycin (HMR-3647): role of the 3-Keto, Group. (poster 2. 10). Proceedings of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones, Seville, Spain. January 26-28 (2000).
49. PIROTH L, DESBIOLLES N, MATEO-PONCE V et al.: HMR 3647 human-like treatment of experimental pneumonia due to penicillin-resistant and erythromycin-resistant Streptococcus pneumoniae. J. Antimicrob. Chemother. (2001) 47:33-42.
50. KUCUKBASMACI O, GONULLU N, AKTAS Z, GUROL D, BERKITEN R: In vitro activity of telithromycin compared with macrolides and fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. Int. J. Antimicrob. Agents. (2003) 22:497-501.
51. BUXBAUM A, FORSTHUBER S, GRANINGER W, GEORGOPOULOS A: Comparative activity of telithromycin against typical community-acquired respiratory pathogens. J. Antimicrob. Chemother. (2003) 52:371-374.
52. PERRET C, LENFANT B, WEINLING E et al.: Pharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteers. Chemotherapy (2002) 48:217-223.
53. MULLER-SERIEYS C, SOLER P, CANTALLOUBE C et al.: Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647). Antimicrob. Agents Chemotber (2001) 45:3104-3108.
54. NAMOUR F, SULTAN E, PASCUAL MH, LENFANT B: Penetration of telithromycin (HMR 3647), a new ketolide antimicrobial, into inflammatory blister fluid following oral administration. J. Antimicrob. Chemother. (2002) 49:1035-1038.
55. KHAIR OA, ANDREWS JM, HONEYBOURNE D, JEVONS G, VACHERON F, WISE R: Lung concentrations of telithromycin after oral dosing. J. Antimicrob. Chemother. (2001) 47:837-840.